India  
NewsR.in
> >

Roche says Tecentriq cocktail helps liver cancer patients live longer

Reuters India Friday, 22 November 2019
Swiss drugmaker Roche on Friday said its immunotherapy Tecentriq combined with its Avastin medicine helped people with the most common form of liver cancer to live longer than with an older drug from Germany's Bayer.
0
shares
ShareTweetSavePostSend
 

Recent related news from verified sources

Genentech Submits Supplemental Biologics License Application to the FDA for Tecentriq in Combination With Avastin for the Most Common Form of Liver Cancer

Genentech Submits Supplemental Biologics License Application to the FDA for Tecentriq in Combination With Avastin for the Most Common Form of Liver Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the completion of a...
Business Wire

Roche's Tecentriq fails trial in form of urothelial cancer

Roche's immunotherapy Tecentriq failed a late-stage clinical trial in a form of urothelial cancer, the Swiss drugmaker said on Friday.
Reuters India

You Might Like


Tweets about this

Environmentally friendly: newsR is hosted on servers powered solely by renewable energy
© 2020 newsR Ltd. All Rights Reserved.
About us  |  Contact us  |  Disclaimer  |  Terms & Conditions  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  In the News  |  DMCA / Content Removal  |  Privacy & Data Protection Policy
How are we doing? FeedbackSend us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter  •  FOLLOW us on Pinterest